Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05313009 · ClinicalTrials.gov registry record · Phase 1
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
A Phase 1 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05313009 is a Phase 1 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 5 participants.
The verdict
NCT05313009, a Phase 1 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small molecule targeting KRAS G12C mutant Non-Small Cell lung cancer.
Interventions
- DRUG Sotorasib and Tarloxotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05313009
The ClinicalTrials.gov registry entry for NCT05313009 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sotorasib and Tarloxotinib is the first listed.
NCT05313009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05313009 about?
NCT05313009 is a clinical study titled "Tarlox and Sotorasib in Patients With KRAS G12C Mutations". This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small molecule targeting KRAS G12C mutant Non-Small Cell lung cancer.
What is the current status of trial NCT05313009?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-03-07. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05313009?
The interventions under investigation include: Sotorasib and Tarloxotinib (DRUG).
Who is sponsoring clinical trial NCT05313009?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.